Lilly’s new product was approved by the ... Both products are priced at a similar level to the glucagon injection kits available on the market, with a list price of $280 per dose, and in the ...

Unlike Lilly's currently marketed obesity treatment Zepbound (tirzepatide), which is given as an injection once a week, retatrutide is a triple-acting GIP/GLP-1/glucagon receptor agonist that is ...

Towards the end of July, the FDA approved Eli Lilly’s intranasal formulation ... many people may have been hesitant to use conventional glucagon kits because the complex preparation felt ...